FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616269701> ?p ?o ?g. }

• W2616269701 endingPage "2782" @default.
• W2616269701 startingPage "2782" @default.
• W2616269701 abstract "Abstract Background: Potent inhibitors of BCR-ABL1have improved remission results and altered post-remission therapy for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dasatinib plus dexamethasone followed by hematopoietic cell transplantation (HCT) promises high response rates, reduced toxicity, and durable remissions. Methods: We conducted a Phase II trial at 17 U.S. centers with the primary objective being to estimate the 3-year overall survival and disease-free survival of patients with Ph+ ALL treated with dasatinib and dexamethasone for remission induction and intensification, central nervous system (CNS) prophylaxis, consolidation with reduced-intensity conditioning (RIC) allogeneic HCT, autologous HCT, or etoposide and cytarabine, and dasatinib-based maintenance. Eligible patients had untreated Ph+ ALL, were ≥18 years old, and had normal cardiac function. Induction (Course I) used dasatinib 140 mg oral daily and dexamethasone 10 mg/m2/day oral or intravenous (IV) days 1-7. For patients with ≤20% blasts in the Course I, Day 15 bone marrow biopsy, intensification (course II) continued daily dasatinib with another 7 days of dexamethasone. Those with >20% lymphoblasts also received vincristine (VCR) and daunorubicin (DNR). Patients (n=3) not in CR/CRi after Course II received a second induction (Course III) with dasatinib, cyclophosphamide, VCR, DNR, and dexamethasone. After Course II or III, CNS prophylaxis (Course IV) consisted of IV VCR and IV, oral, and intrathecal methotrexate (MTX). Dasatinib was restarted at serum [MTX] <0.05 microM. Course V consisted of HCT or chemotherapy. Patients aged 18-70 years with an HLA-matched donor underwent RIC allogeneic HCT; otherwise they underwent autologous HCT. Allogeneic HCT conditioning used fludarabine 30 mg/m2/day IV day -7 through -3, alemtuzumab 20 mg/day IV day -7 through -3, and melphalan 140 mg/m2 once on day -2. GVHD prophylaxis with tacrolimus began day -2. Patients undergoing autologous HCT received etoposide 10 mg/kg/day (age >65 years, 5 mg/kg/day) continuous IV for 4 days and cytarabine 2 g/m2 (age >65 years, 1 g/m2) IV every 12 hours for 8 doses (EA) then G-CSF for mobilization. Autologous HCT conditioning used melphalan 100 mg/m2/day on days -2 and -1. Patients >70 years or unable to undergo HCT received EA alone. Dasatinib maintenance (Course VI) began on day 30 of Course V and continued for 12 months and until 2 consecutively negative bone marrow BCR-ABL1RT-PCR assays 3 months apart or until relapse. Dasatinib levels were measured on day 15 of induction. Results: Sixty-six patients enrolled from 12/15/2010 to 11/14/2014; 65 received dasatinib and are evaluable. Median age was 60 years (22-87); 49% were male. Median presenting WBC count was 23.1 x 103/ul (0.3-453.6). No deaths occurred during induction or intensification. CR or CRi occurred 31 patients (48%) by Day 15 of induction and in 62 patients overall (95%; CR 86%). Median dasatinib levels in serum and CSF on Day 15 of induction were 30.3 ng/mL (<3-308) and 0.29 ng/mL (<0.2-1.37), respectively suggesting approximately 1% of plasma dasatinib penetrates into the CSF, less than the unbound fraction (6%). Fifty-four patients started Course IV, 38 Course V, and 37 Course VI. Fourteen patients continue on protocol therapy. Of 38 patients receiving Course V, 22 had allogeneic HCT, 6 had autologous HCT, and 10 had EA chemotherapy. Median age of allogeneic HCT recipients was 61 years (31-69). Robust autologous stem cell mobilization was observed [median CD34+ cell count, 90 x 106/kg (31-166, n=6)]. Dasatinib maintenance was feasible after allogeneic HCT, autologous HCT, and chemotherapy alone with no missed doses in 59%, 83%, and 63% of cycles, respectively. Ten patients have relapsed with one isolated CNS relapse. No relapses have occurred after allogeneic HCT with 3 relapses after autologous HCT and one after Course V EA alone. Median follow up for survivors is 22.8 months (longest, 51 months). There have been 23 deaths: 5 treatment-related (4 after allogeneic HCT, 1 after course V EA), 16 disease-related and 2 unrelated. Conclusions: Dasatinib with dexamethasone yields CR rates comparable to those reported with tyrosine kinase inhibitors combined with conventional chemotherapy. Post-remission therapy with reduced-intensity allogeneic HCT, autologous HCT, or chemotherapy followed by dasatinib maintenance is feasible. Survival follow up is maturing. Disclosures Stock: Sigma-Tau: Honoraria, Research Funding; Royalties for a chapter in Up to Date: Patents & Royalties; ADC Therapeutics: Honoraria; Amgen: Honoraria; Gilead Sciences: Honoraria. Beumer:Bristol-Myers Squibb: Research Funding. Stone:Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; Juno Therapeutics: Consultancy; Karyopharm: Consultancy; Sunesis Pharmaceuticals: Consultancy; Agios: Consultancy; Amgen: Consultancy; Celator: Consultancy; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy; Jansen: Consultancy; Merck: Consultancy; ONO: Consultancy; Roche: Consultancy; Seattle Genetics: Consultancy; Xenetic Biosciences: Consultancy. Larson:Bristol-Myers Squibb: Consultancy; Astellas: Consultancy, Research Funding." @default.
• W2616269701 created "2017-05-26" @default.
• W2616269701 creator A5000335847 @default.
• W2616269701 creator A5003966906 @default.
• W2616269701 creator A5005939966 @default.
• W2616269701 creator A5007647176 @default.
• W2616269701 creator A5007840845 @default.
• W2616269701 creator A5007847102 @default.
• W2616269701 creator A5011144900 @default.
• W2616269701 creator A5027371881 @default.
• W2616269701 creator A5030342776 @default.
• W2616269701 creator A5039028985 @default.
• W2616269701 creator A5048992211 @default.
• W2616269701 creator A5069208658 @default.
• W2616269701 creator A5071023119 @default.
• W2616269701 creator A5072420982 @default.
• W2616269701 creator A5085783292 @default.
• W2616269701 date "2016-12-02" @default.
• W2616269701 modified "2023-09-30" @default.
• W2616269701 title "A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Hematopoietic Cell Transplantation for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: CALGB Study 10701 (Alliance)" @default.
• W2616269701 doi "https://doi.org/10.1182/blood.v128.22.2782.2782" @default.
• W2616269701 hasPublicationYear "2016" @default.
• W2616269701 type Work @default.
• W2616269701 sameAs 2616269701 @default.
• W2616269701 citedByCount "6" @default.
• W2616269701 countsByYear W26162697012017 @default.
• W2616269701 countsByYear W26162697012018 @default.
• W2616269701 countsByYear W26162697012020 @default.
• W2616269701 countsByYear W26162697012023 @default.
• W2616269701 crossrefType "journal-article" @default.
• W2616269701 hasAuthorship W2616269701A5000335847 @default.
• W2616269701 hasAuthorship W2616269701A5003966906 @default.
• W2616269701 hasAuthorship W2616269701A5005939966 @default.
• W2616269701 hasAuthorship W2616269701A5007647176 @default.
• W2616269701 hasAuthorship W2616269701A5007840845 @default.
• W2616269701 hasAuthorship W2616269701A5007847102 @default.
• W2616269701 hasAuthorship W2616269701A5011144900 @default.
• W2616269701 hasAuthorship W2616269701A5027371881 @default.
• W2616269701 hasAuthorship W2616269701A5030342776 @default.
• W2616269701 hasAuthorship W2616269701A5039028985 @default.
• W2616269701 hasAuthorship W2616269701A5048992211 @default.
• W2616269701 hasAuthorship W2616269701A5069208658 @default.
• W2616269701 hasAuthorship W2616269701A5071023119 @default.
• W2616269701 hasAuthorship W2616269701A5072420982 @default.
• W2616269701 hasAuthorship W2616269701A5085783292 @default.
• W2616269701 hasConcept C126322002 @default.
• W2616269701 hasConcept C141071460 @default.
• W2616269701 hasConcept C2776694085 @default.
• W2616269701 hasConcept C2776755627 @default.
• W2616269701 hasConcept C2777583451 @default.
• W2616269701 hasConcept C2778119113 @default.
• W2616269701 hasConcept C2778729363 @default.
• W2616269701 hasConcept C2779429289 @default.
• W2616269701 hasConcept C2779536868 @default.
• W2616269701 hasConcept C2780401358 @default.
• W2616269701 hasConcept C2911091166 @default.
• W2616269701 hasConcept C71924100 @default.
• W2616269701 hasConcept C90924648 @default.
• W2616269701 hasConceptScore W2616269701C126322002 @default.
• W2616269701 hasConceptScore W2616269701C141071460 @default.
• W2616269701 hasConceptScore W2616269701C2776694085 @default.
• W2616269701 hasConceptScore W2616269701C2776755627 @default.
• W2616269701 hasConceptScore W2616269701C2777583451 @default.
• W2616269701 hasConceptScore W2616269701C2778119113 @default.
• W2616269701 hasConceptScore W2616269701C2778729363 @default.
• W2616269701 hasConceptScore W2616269701C2779429289 @default.
• W2616269701 hasConceptScore W2616269701C2779536868 @default.
• W2616269701 hasConceptScore W2616269701C2780401358 @default.
• W2616269701 hasConceptScore W2616269701C2911091166 @default.
• W2616269701 hasConceptScore W2616269701C71924100 @default.
• W2616269701 hasConceptScore W2616269701C90924648 @default.
• W2616269701 hasIssue "22" @default.
• W2616269701 hasLocation W26162697011 @default.
• W2616269701 hasOpenAccess W2616269701 @default.
• W2616269701 hasPrimaryLocation W26162697011 @default.
• W2616269701 hasRelatedWork W2039382964 @default.
• W2616269701 hasRelatedWork W2047930003 @default.
• W2616269701 hasRelatedWork W2056602708 @default.
• W2616269701 hasRelatedWork W2091361215 @default.
• W2616269701 hasRelatedWork W2252336101 @default.
• W2616269701 hasRelatedWork W2409349546 @default.
• W2616269701 hasRelatedWork W2412065402 @default.
• W2616269701 hasRelatedWork W2412181118 @default.
• W2616269701 hasRelatedWork W2886757491 @default.
• W2616269701 hasRelatedWork W3094869008 @default.
• W2616269701 hasVolume "128" @default.
• W2616269701 isParatext "false" @default.
• W2616269701 isRetracted "false" @default.
• W2616269701 magId "2616269701" @default.
• W2616269701 workType "article" @default.